A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer

Dongling Zou, Mingfang Guo, Qi Zhou, Dongling Zou, Mingfang Guo, Qi Zhou

Abstract

Purpose: To evaluate the effectiveness and safety of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during chemoradiotherapy in patients with cervical cancer.

Methods: From August 2018 to April 2020, 60 patients who were pathologically confirmed as cervical cancer were randomly divided into two groups at a ratio of 2:1: PEG-modified-rhG-CSF experimental group and control group. The primary endpoints were the incidence of grade 3-4 neutropenia. Secondary endpoints included the duration of grade 3-4 neutropenia, the incidence of grade 4 neutropenia, the incidence of febrile neutropenia (FN), delay rate of chemotherapy, prolonged time of chemotherapy, time to complete radiotherapy and safety.

Results: The incidence of grade 3-4 neutropenia in the experimental group was significantly lower than the control group (10% vs. 77.78%, P < 0.001). However, there was no statistical significance between the two groups in the duration of grade 3-4 neutropenia (3.75 days vs. 5.07 days, P = 0.871). The experimental group was better than the control group in the incidence of grade 4 neutropenia, the incidence of FN and delay rate of chemotherapy, and the difference was statistically significant (P < 0.05). Besides, the prolonged time of chemotherapy and the time to complete radiotherapy in the experimental group were less than those in the control group, but the difference was not statistically significant (P > 0.05). The incidence of adverse events in the experimental group and control group were 55.00 and 94.44%, respectively, and the difference was statistically significant (P = 0.003).

Conclusion: PEG-rhG-CSF preventive treatment used in the course of chemoradiotherapy for patients with cervical cancer can reduce the incidence of neutropenia and improve the incidence of delayed chemotherapy cycles.

Trial registration: ClinicalTrials.gov , NCT04542356 . Registered 9 September 2020 - Retrospectively registered.

Keywords: Cervical Cancer; Concurrent Radiochemotherapy; Neutropenia; Pegylated recombinant human granulocyte colony stimulating factor.

Conflict of interest statement

This study was supported by the Qilu pharmaceutical Co. Ltd.

Figures

Fig. 1
Fig. 1
Summarized data presenting the analysis of endpoints

References

    1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–2686. doi: 10.1093/annonc/mdr015.
    1. Tilahun Y, Lew C, Belayihun B, Lulu Hagos K, Asnake M. Improving contraceptive access, use, and method mix by task sharing Implanon insertion to frontline health workers: the experience of the integrated family health program in Ethiopia. Glob Health Sci Pract. 2017;5(4):592–602. doi: 10.9745/GHSP-D-17-00215.
    1. Mądry R, Popławska L, Haslbauer F, Šafanda M, Ghizdavescu D, Benkovicova J, Csőszi T, Mihaylov G, Niepel D, Jaeger C, Frkanova I, Macovei A, Staudigl C. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wien Klin Wochenschr. 2016;128(7–8):238–247. doi: 10.1007/s00508-015-0917-1.
    1. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–12.
    1. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167. doi: 10.1200/JCO.2006.08.8823.
    1. Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484. doi: 10.1093/annonc/mdt226.
    1. Giebel S, Thomas X, Hallbook H, Geissler K, Boiron JM, Huguet F, Koller E, Jaeger U, Smedmyr B, Hellmann A, Holowiecki J. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. Eur J Cancer. 2012;48(3):360–367. doi: 10.1016/j.ejca.2011.11.023.
    1. Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev. 1996;28(4):625–658. doi: 10.3109/03602539608994020.
    1. CJ XJ, Wang JF, Zhang BH, Zeng XH, Zheng H, Zhang Y, Cai L, Wu YD, Yao Q, Zhao XC, Mao WD, Jiang AM, Chen SS, Yang SE, Wang SS, Wang JH, Pan YY, Ren BY, Chen YJ, Ouyang LZ, Lei KJ, Gao JH, Huang WH, Huang Z, Shou T, He YL, Cheng J, Sun Y, Li WM, Cui SD, Wang X, Rao ZG, Ma H, Liu W, Wu XY, Shen WX, Cao FL, Xiao ZM, Wu B, Tian SY, Meng D, Shen P, Wang BY, Wang Z, Zhang J, Wang L, Hu XC. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. Breast Cancer Res Treat. 2018;168(2):389–399. doi: 10.1007/s10549-017-4609-6.
    1. Takashi Yoshida SN, Ohtake S, Okafuji K, Kobayashi K, Kondo K, Kanno M, Matano S, Matsuda T, Kanai M, Sugimoto R, Ogawa M, Takaku F. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer. 1990;66(9):1904–1909. doi: 10.1002/1097-0142(19901101)66:9<1904::AID-CNCR2820660908>;2-V.
    1. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451–1458. doi: 10.1016/S1359-6446(05)03575-0.
    1. Lee KHKJ, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10–09. Support Care Cancer. 2016;24(4):1709–1717. doi: 10.1007/s00520-015-2963-7.
    1. Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011;27(1):79–86. doi: 10.1185/03007995.2010.536527.
    1. Gabrilove JL. An analysis of current neutropenia therapies, including pegfilgrastim. Clin Cornerstone. 2006;8(Suppl 5):S19–S28. doi: 10.1016/S1098-3597(06)80055-4.
    1. Zhai Y, Zhao Y, Lei J, Su Z, Ma G. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J Biotechnol. 2009;142(3–4):259–266. doi: 10.1016/j.jbiotec.2009.05.012.
    1. Zhou CHY, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J. A randomized multicenter phase III study of single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim biosimilar, for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small-cell lung Cancer (NSCLC) Clin Lung Cancer. 2016;17(2):119–127. doi: 10.1016/j.cllc.2015.12.002.
    1. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study Group A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35. doi: 10.1093/annonc/mdg019.
    1. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21(3):514–519. doi: 10.1200/JCO.2003.03.040.
    1. Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, Hong Y, Wang L, Zhen H, Lin L. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2018;82(4):607–613. doi: 10.1007/s00280-018-3639-z.
    1. Sekine ISM, Ito Y, Horinouchi H, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Kubota K, Tamura T. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):953–959. doi: 10.1016/j.ijrobp.2011.01.008.
    1. Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, Koutras A, Fountzilas G, Maniadakis N. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer. 2015;23(7):2045–2051. doi: 10.1007/s00520-014-2555-y.
    1. Liu F, Du Y, Cai B, Yan M, Yang W, Wang Q. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy. J Cancer Res Ther. 2017;13(5):790–795. doi: 10.4103/jcrt.JCRT_320_17.
    1. Beesley VL, Smith DD, Nagle CM, Friedlander M, Grant P, DeFazio A, Webb PM. Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer. 2018;26(12):4133–4142. doi: 10.1007/s00520-018-4284-0.
    1. Chunyun Z, Jie S, Wu Y, Shen W, Yongming C, Duanyuan S, Zongpeng z. Pharmacokinetics and pharmacodynamics study of PEGylated recombinant human granulocyte colony-stimulating factor injection in healthy volunteers. Drugs Clin. 2017;32(9):1614–1619.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe